Steve Weitman

Steve Weitman obtained his M.D. and Ph.D. at the Medical College of Wisconsin, USA. He is board certified in Pediatric Hematology/Oncology. Steve was most recently Chief Medical Officer and Member of the Executive Committee at ILEX Oncology where he led ILEX's successful development of clofarabine (Clolar) and guided that product through a successful ODAC and FDA approval. Steve is inventor on numerous patents and author of over 200 papers, abstracts and chapters in the medical literature. Steve serves on the Board of Directors of several companies and is a consultant to various biotech and pharma companies, Associate Editor of Investigational New Drugs and reviewer for multiple journals including the American Journal of Pediatric Hematology/Oncology, Clinical Cancer Research, Cancer Research and the Journal of Clinical Oncology. In addition to his industry experience, Steve has held the positions of Assistant and Associate Professor at Southwestern Medical Center, Medical College of Wisconsin, University of Texas Health Science Center at San Antonio (with tenure) and Director of Adult and Pediatric Translational Research and holder of the Zachry Chair for Translational Research at the Institute for Drug Development in San Antonio.